Despite that sustained NRF2 activation is considered a driver of the malignant progression of several types of tumors, its role in breast cancer (migration, invasion and metastasis) still remains a matter of intense debate due to conflicting data. This evidence concerns the gene NFE2L2 and breast carcinoma.